Synageva says sebelipase alfa continues to reduce liver damage

Synageva BioPharma announced presentations at the upcoming LDN WORLD Symposium being held February 13-15 in Orlando, Florida. During an oral presentation on Friday, February 15, at 1:00 PM EST, Dr. Manisha Balwani will present 38-week data from the Phase I/II extension study of sebelipase alfa in adults with late onset lysosomal acid lipase deficiency. An additional poster at the LDN WORLD Symposium will highlight the ability of SBC-103 to reduce the accumulation of substrate in the brain of a Mucopolysaccharidosis IIIB animal model. Sebelipase alfa effects observed in this study at 24 weeks were sustained through 38 weeks. Sebelipase alfa continues to reduce liver damage with sustained reductions in both ALT and AST, frequently into the normal range. In addition, maintenance of the improvements in the dyslipidemia associated with LAL Deficiency was also observed. Sebelipase alfa produced mean percent decreases for ALT and AST from the initial baseline to week 38 of the extension study of 54% and 40%, respectively. Sebelipase alfa was generally well tolerated throughout the initial 38 weeks of the extension study, the company said.

View Comments (0)